Shattuck Labs, Inc. (NASDAQ:STTK) Receives $7.50 Consensus Target Price from Brokerages

Shares of Shattuck Labs, Inc. (NASDAQ:STTK) have earned a consensus rating of “Moderate Buy” from the seven research firms that are currently covering the company, Marketbeat Ratings reports. Four analysts have rated the stock with a hold rating, one has given a buy rating and two have given a strong buy rating to the company. The average 1 year price objective among brokers that have covered the stock in the last year is $7.50.

Several research analysts recently weighed in on STTK shares. Leerink Partners assumed coverage on Shattuck Labs in a research report on Monday, March 17th. They issued an “outperform” rating and a $4.00 price objective for the company. HC Wainwright reaffirmed a “neutral” rating on shares of Shattuck Labs in a research report on Thursday, March 27th. Leerink Partnrs raised shares of Shattuck Labs to a “strong-buy” rating in a research report on Monday, March 17th. Finally, Needham & Company LLC reissued a “hold” rating on shares of Shattuck Labs in a research report on Thursday, March 27th.

Shattuck Labs Stock Performance

NASDAQ STTK opened at $0.94 on Tuesday. Shattuck Labs has a fifty-two week low of $0.69 and a fifty-two week high of $11.76. The firm has a market capitalization of $45.01 million, a P/E ratio of -0.61 and a beta of 1.74. The stock has a 50-day simple moving average of $1.01 and a two-hundred day simple moving average of $1.15.

Shattuck Labs (NASDAQ:STTK) last announced its earnings results on Thursday, May 1st. The company reported ($0.27) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.29) by $0.02. Shattuck Labs had a negative net margin of 1,156.46% and a negative return on equity of 61.92%. As a group, analysts forecast that Shattuck Labs will post -1.48 earnings per share for the current year.

Hedge Funds Weigh In On Shattuck Labs

Several institutional investors have recently added to or reduced their stakes in the business. Prosight Management LP grew its position in Shattuck Labs by 15.1% during the fourth quarter. Prosight Management LP now owns 6,638,935 shares of the company’s stock valued at $8,033,000 after acquiring an additional 873,409 shares during the period. Adage Capital Partners GP L.L.C. boosted its position in Shattuck Labs by 61.2% in the 4th quarter. Adage Capital Partners GP L.L.C. now owns 4,675,000 shares of the company’s stock valued at $5,657,000 after buying an additional 1,775,000 shares during the last quarter. 683 Capital Management LLC purchased a new stake in Shattuck Labs during the 4th quarter worth approximately $1,270,000. Geode Capital Management LLC increased its position in shares of Shattuck Labs by 0.9% in the 3rd quarter. Geode Capital Management LLC now owns 912,202 shares of the company’s stock worth $3,184,000 after purchasing an additional 8,133 shares during the last quarter. Finally, Takeda Pharmaceutical Co. Ltd. acquired a new position in shares of Shattuck Labs in the 4th quarter worth approximately $624,000. 58.74% of the stock is currently owned by institutional investors and hedge funds.

Shattuck Labs Company Profile

Shattuck Labs, Inc, a clinical-stage biotechnology company, develops therapeutics for the treatment of cancer and autoimmune disease in the United States. The company's lead product candidate is SL-172154, which is in Phase 1 clinical trial for the treatment of ovarian, fallopian tube, and peritoneal cancers.